{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/mastitis-breast-abscess/prescribing-information/co-amoxiclav/","result":{"pageContext":{"chapter":{"id":"3354cafa-cf61-54b5-8be9-14286cac7d43","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav","depth":2,"htmlHeader":"<!-- begin field 1ad654f7-23d9-42a2-9a40-a78200c51c81 --><h2>Co-amoxiclav</h2><!-- end field 1ad654f7-23d9-42a2-9a40-a78200c51c81 -->","summary":"","htmlStringContent":"<!-- begin item e553b797-1b03-4d71-857a-a78200c51ae6 --><!-- end item e553b797-1b03-4d71-857a-a78200c51ae6 -->","topic":{"id":"612445a9-31b6-5130-bb99-4389c0f9c4af","topicId":"8dd98aac-dd7a-4981-bb01-5e666b4686b6","topicName":"Mastitis and breast abscess","slug":"mastitis-breast-abscess","lastRevised":"January 2021","chapters":[{"id":"d054cbf1-e596-5afd-8a75-f3d051c621dc","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"de83cb42-8301-5164-81a9-f0c4ab5a83c2","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"610b1eb8-dd62-5e7e-b3bf-deb28c7072aa","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"c44cbf7c-02c4-5674-abb6-1c6be6131e3b","slug":"changes","fullItemName":"Changes"},{"id":"9d333c13-3643-5811-9a29-a919983994aa","slug":"update","fullItemName":"Update"}]},{"id":"f993c606-c828-51da-a43a-6029a7e07f40","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"a4f11480-406f-5573-9e6b-b2747a513a11","slug":"goals","fullItemName":"Goals"},{"id":"5020b6cc-9441-50c0-b8dd-94fcf8bdf761","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"948e09e3-ff32-5344-a06f-e0a9331eff4f","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"e253dff2-3341-5c3a-8c2c-a8c5c9d27491","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"7a7fe239-eefb-5a7a-936c-c1c01d919b6e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"844a01a3-e6d9-5962-905c-52aaa284973a","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"13965c3c-cc8a-575f-8e2d-056c9590196a","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"edd589e4-be3e-52d6-b1ea-c2095f08f38e","slug":"definition","fullItemName":"Definition"},{"id":"06b05f0c-3f18-5d1a-994a-02d388348b53","slug":"causes","fullItemName":"Causes"},{"id":"ac2b0ec4-d2dd-5b82-999f-aa4fb681433e","slug":"predisposing-factors","fullItemName":"Predisposing factors"},{"id":"033ddd74-dfdc-5a2d-bb82-453baebee36f","slug":"prevalence","fullItemName":"Prevalence"},{"id":"9ccd068b-aec1-59bb-a0dc-497e330227b3","slug":"prognosis","fullItemName":"Prognosis"},{"id":"bf45f222-3e69-50c6-b73f-cd089ff22c65","slug":"complications","fullItemName":"Complications"}]},{"id":"1facde51-ce1f-55fa-889f-f079ac8b1283","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"4d19871b-504c-5d1d-8e27-298e0a8e40b2","slug":"when-to-suspect-mastitis","fullItemName":"When to suspect mastitis"},{"id":"1a7eb0d1-33d6-539d-bfc3-0b12f1ec6451","slug":"when-to-suspect-a-breast-abscess","fullItemName":"When to suspect a breast abscess"},{"id":"3478864a-a09e-5e3f-ab1e-bd6dc34d0ae1","slug":"investigations","fullItemName":"Investigations"},{"id":"f70b7f79-5c5c-5a9d-a586-dad7ec33698c","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"1bdc74c8-e4f7-574c-a93a-ea9103718273","fullItemName":"Management","slug":"management","subChapters":[{"id":"7d9d079a-de35-5f76-8cfe-4303cce22c3e","slug":"management-lactating-women","fullItemName":"Scenario: Management - lactating women"},{"id":"95e2db4c-1f7a-5dfe-b04b-5edb440448bd","slug":"management-non-lactating-women","fullItemName":"Scenario: Management - non-lactating women"},{"id":"d1bd1c0d-5efe-5925-92a2-57663e0af1d5","slug":"management-breast-abscess","fullItemName":"Scenario: Management - breast abscess"}]},{"id":"d2222456-9dbf-5408-9e2a-d06f803d315e","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"02c4d465-606a-5a45-bb76-7884e6655d29","slug":"flucloxacillin","fullItemName":"Flucloxacillin"},{"id":"35a080bd-68dc-5e30-8e45-c15b80ad6691","slug":"erythromycin-claithromycin","fullItemName":"Erythromycin and claithromycin"},{"id":"3354cafa-cf61-54b5-8be9-14286cac7d43","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"6882319d-cec4-58ac-a5fb-bfad5a8c44b5","slug":"metronidazole","fullItemName":"Metronidazole"}]},{"id":"5ca61020-4e7e-58c8-89de-963d0f9fad55","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"cdcf64dc-7d30-54dc-a4b3-c2cbb2e11318","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"9ed2bf1e-0ab0-5318-ab26-7125ea334bc2","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"a07ffae7-9042-5683-b005-a39cb64cfe07","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"3647fb21-13e1-5087-8638-500053de452d","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d3f0e67e-27f7-5dab-bf77-6fd2fb6c04aa","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"c1eba960-eb26-5c75-a69c-d1b75d6bb18b","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"e3453acf-65bd-5b33-854f-a6e08be6d75c","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"d2222456-9dbf-5408-9e2a-d06f803d315e","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"3c020f32-2a82-552e-b672-8d50abedb1f9","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 2b722baa-37bf-4200-9165-a78200c68f07 --><h3>Contraindications and cautions</h3><!-- end field 2b722baa-37bf-4200-9165-a78200c68f07 -->","summary":"","htmlStringContent":"<!-- begin item 81e56b70-22b0-4d76-b5ae-a78200c68d37 --><!-- begin field 41fafe2c-f3c3-442e-9826-a78200c68f07 --><ul><li><strong>Do not prescribe co-amoxiclav to people with a history of:</strong><ul><li>A <em>true</em> penicillin hypersensitivity. Gastrointestinal adverse effects alone (such as nausea, vomiting, or diarrhoea) do <em>not</em> constitute an allergy to penicillin.</li><li>Penicillin-associated hepatic dysfunction.</li></ul></li><li><strong>Prescribe co-amoxiclav with caution to people with:</strong><ul><li>Hypersensitivity to cephalosporins.</li><li>Hepatic impairment.</li><li>Chronic kidney disease (CKD) — reduce the dose if the estimated glomerular filtration rate (eGFR) is 30 mL/minute/1.73 m<sup>2</sup> or less.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/mastitis-breast-abscess/references/\">ABPI, 2020c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/mastitis-breast-abscess/references/\">BNF, 2021</a>]</p><!-- end field 41fafe2c-f3c3-442e-9826-a78200c68f07 --><!-- end item 81e56b70-22b0-4d76-b5ae-a78200c68d37 -->","subChapters":[]},{"id":"112b4c7d-488c-56fe-b739-4dc9f9c4521b","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 448d17b3-4a88-4799-9d20-a78200c6b97d --><h3>Adverse effects</h3><!-- end field 448d17b3-4a88-4799-9d20-a78200c6b97d -->","summary":"","htmlStringContent":"<!-- begin item c79ffd50-c380-4bf0-a4d6-a78200c6b77f --><!-- begin field e2b71218-6392-42db-b364-a78200c6b97d --><ul><li><strong>Nausea, vomiting, skin rash, and diarrhoea</strong> are the most common adverse effects of co-amoxiclav.<ul><li>Consider pseudomembranous colitis if a person develops severe diarrhoea during or after treatment with co-amoxiclav. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>.</li></ul></li><li><strong>Co-amoxiclav</strong> can also cause fungal infection and vaginitis.</li><li><strong>Anaphylaxis (delayed or immediate)</strong> is a serious but rare adverse effect of co-amoxiclav. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/angio-oedema-anaphylaxis/\">Angio-oedema and anaphylaxis</a>.</li><li><strong>Hepatitis and cholestatic jaundice</strong> may rarely occur following treatment with co-amoxiclav.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/mastitis-breast-abscess/references/\">ABPI, 2020c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/mastitis-breast-abscess/references/\">BNF, 2021</a>]</p><!-- end field e2b71218-6392-42db-b364-a78200c6b97d --><!-- end item c79ffd50-c380-4bf0-a4d6-a78200c6b77f -->","subChapters":[]},{"id":"81389811-f9b3-59a1-b566-60b10bcb0857","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field cf4aa89e-75b2-418e-bf8e-a78200c6dbb5 --><h3>Drug interactions</h3><!-- end field cf4aa89e-75b2-418e-bf8e-a78200c6dbb5 -->","summary":"","htmlStringContent":"<!-- begin item d63d0918-c9a0-4d19-a4ec-a78200c6d860 --><!-- begin field 848562bc-d30b-4e8c-a3e7-a78200c6dbb5 --><ul><li><strong>Key drug interactions with co-amoxiclav include: </strong><ul><li><strong>Allopurinol </strong>— be aware that concomitant use of allopurinol and amoxicillin may increase the incidence of skin rashes.</li><li><strong>Anticoagulants (for example warfarin) </strong>— prolongation of prothrombin time has been reported in people taking penicillins and warfarin concurrently.<ul><li>Monitor the prothrombin time or international normalized ratio (INR) more closely with the addition or withdrawal of penicillin. Adjustment of the anticoagulant dose may be necessary.</li></ul></li><li><strong>Methotrexate </strong>— penicillins may reduce the excretion of methotrexate. The interaction is not usually serious and risk factors are unknown (even people on low doses of methotrexate have been affected).<ul><li>Monitor methotrexate levels more closely. One recommendation is to carry out twice weekly platelet and white cell counts for 2 weeks initially, with the measurement of methotrexate levels if toxicity is suspected.</li></ul></li></ul></li><li><strong>Oral hormonal contraception </strong>— additional contraceptive precautions are <em>not</em> required during or after courses of penicillins.<ul><li>However, advise women on the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the section on vomiting or diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/mastitis-breast-abscess/references/\">FSRH, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/mastitis-breast-abscess/references/\">ABPI, 2020c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/mastitis-breast-abscess/references/\">Preston, 2020</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/mastitis-breast-abscess/references/\">BNF, 2021</a>]</p><!-- end field 848562bc-d30b-4e8c-a3e7-a78200c6dbb5 --><!-- end item d63d0918-c9a0-4d19-a4ec-a78200c6d860 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}